Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEP-3 vaccine + sargramostim + temozolomide
- Development stage
- Phase 2
- Lead developer
- Duke University Medical Center
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intradermal, Oral
01
Overview
A combination therapy consisting of PEP-3 vaccine (a synthetic peptide vaccine targeting EGFRvIII), sargramostim (GM-CSF, an immune stimulant), and temozolomide (an oral alkylating chemotherapy agent). This regimen is primarily studied for the treatment of glioblastoma multiforme. The PEP-3 vaccine consists of a 13-amino acid peptide conjugated to keyhole limpet hemocyanin (KLH) to enhance immunogenicity. Sargramostim is used as an adjuvant to boost immune response, while temozolomide provides direct cytotoxic effects against tumor cells.
- Other names
- PEP-3-KLH conjugate vaccine + sargramostim + temozolomide
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA
Beyond the preview
Go deeper on PEP-3 vaccine + sargramostim + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEP-3 vaccine + sargramostim + temozolomide.